| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chairman & CEO | Chief Executive Officer +1 more
2 companies
Daniel R Chard is Director at MED, with reported holdings spanning 2 companies. Daniel R Chard's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Our model assigns Daniel R Chard a middling insider score of 68/100, based on 9 past trades. Over a 12-month horizon, 62.5% of those trades were profitable, with an average 12-month return of +9.4%.
Daniel R Chard's largest disclosed position is in MED as Director, worth about $1.6M. The MED filings lean toward selling, a net 33,934 shares.
Daniel R Chard has 33 Form 4 filings on record from February 2015 to September 2026, across 2 companies: Director at Medifast (MED), 2016–2026; President Global Sales & Operations at Nu Skin Enterprises (NUS), 2015.
The 107 reported transactions were 48 open-market sales, 27 tax withholdings, 12 stock awards and 8 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $541K and 5 sales worth about $10.8M.
The largest open-market purchase was 17,678 shares of MED at an average $10.11 on March 20, 2026, about $179K.
The largest open-market sale was 15,115 shares of MED at an average $285.21 on June 14, 2021, about $4.3M. Twelve months later MED was down 35%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | MED Medifast, Inc. | Director | Sell10b5-1 | 19,089 | $11.85 | $226,288.77 | -12.8% | - | - | |
| Mar 20, 2026 | MED Medifast, Inc. | Chairman & CEO | Buy | 17,678 | $10.11 | $178,724.58 | New | +10.4% | - | |
| Jun 13, 2025 | MED Medifast Inc | Chairman & CEO | Buy | 381 | $13.13 | $5,002.53 | +0.3% | +7.2% | -8.4% | |
| May 5, 2022 | MED Medifast Inc | Chairman & CEO | Buy | 431 | $183.25 | $78,995.04 | +0.4% | -5.4% | -48.4% | |
| Feb 4, 2022 | MED Medifast Inc | Chairman & CEO | Buy | 690 | $186.40 | $128,667.07 | +0.7% | -1.8% | -35.5% | |
| Jun 17, 2021 | MED Medifast Inc | Chairman & CEO | Sell | 6,365 | $263.55 | $1,677,518.72 | -5.6% | -18.2% | -32.2% | |
| Jun 16, 2021 | MED Medifast Inc | Chairman & CEO | Sell | 13,520 | $278.00 | $3,758,577.06 | -10.7% | -19.2% | -33.8% | |
| Jun 14, 2021 | MED Medifast Inc | Chairman & CEO | Sell | 15,115 | $285.21 | $4,311,011.56 | -10.7% | -16.2% | -34.6% | |
| Nov 8, 2018 | MED Medifast Inc | Chief Executive Officer | Buy | 975 | $153.28 | $149,448.00 | +8.3% | - | - | |
| Jul 6, 2015 | NUS Nu Skin Enterprises, Inc. | President Global Sales & Operations | Sale+OE | 17,500 | $46.67 | $816,725.00 | -26.7% | - | - |